BioCentury | Jan 12, 2021
Emerging Company Profile

Atalanta’s next-gen RNAi branches deeper into brain, hooks Biogen and Genentech

...The sizes of the three components are undisclosed.The University of Massachusetts Medical School...
BioCentury | Aug 5, 2020
Emerging Company Profile

Nura reveals neuroprotective lead target, first part of its neurology one-two punch

...serves as chairman. The company’s scientific founders are Marc Freeman, a professor of neurobiology at University of Massachusetts Medical School...
BioCentury | Jun 26, 2020
Distillery Therapeutics

Promoting Golgi fragmentation to treat pancreatic cancer

...Natl. Acad. Sci. USA ; published online May 19, 2020 doi:10.1073/pnas.2005156117 CONTACT: Michael R. Green, University of Massachusetts Medical School...
...Mass. email: Michael.Green@umassmed.edu CONTACT: Narendra Wajapeyee, University of Alabama at Birmingham, Birmingham, Ala. email: nwajapey@uab.edu Claire Quang University of Massachusetts Medical School University...
BioCentury | Jun 11, 2020
Deals

June 10 Quick Takes: Lilly enters deal with Evox on exosome therapies; plus Sanofi-Alphamab, CSL-Vitaeris, Canbridge-UMass and Find’s debut

...therapies Canbridge Pharmaceuticals Inc. has initiated a research collaboration with the Gene Therapy Center at University of Massachusetts Medical School...
...University of Illinois in Chicago. Targets IL-6 - Interleukin-6 BioCentury Staff Eli Lilly and Co. Evox Therapeutics Ltd. Vitaeris Inc. Sanofi University of Massachusetts Medical School Alphamab...
BioCentury | May 9, 2020
Deals

Columbia’s peptide nucleic acid technology draws Fortress into rare discovery deal

...formation of gene therapy subsidiary Aevitas Therapeutics Inc., which has a research agreement with the University of Massachusetts Medical School...
BioCentury | Apr 17, 2020
Emerging Company Profile

Rgenta: enhancing interactions between RNA and RNA-binding proteins

...and CEO Simon Xi. Weng, who heads Rgenta’s scientific advisory board, is a professor at University of Massachusetts Medical School...
...Clinical status: Preclinical Founded: 2019 by Zhiping Weng, Simon Xi and Travis Wager University collaborators: University of Massachusetts Medical School...
BioCentury | Apr 10, 2020
Product Development

COVID-19 roundup: New immune targets to address pandemic; plus updates from CanSino, Arcturus, Fujifilm and more

...50 patients, will be conducted with Brigham and Women’s Hospital, Massachusetts General Hospital and the University of Massachusetts Medical School...
BioCentury | Jan 31, 2020
Distillery Therapeutics

Crry gene therapy to treat multiple sclerosis

...published online Dec. 26, 2019 doi:10.1016/j.immuni.2019.12.004 CONTACT: Dorothy P. Schafer, University of Massachusetts Medical School, Worcester, Mass. email: dorothy.schafer@umassmed.edu Claire Quang University of Massachusetts Medical School...
BioCentury | Nov 27, 2019
Company News

Management tracks: Ultragenyx COO to step down next year; plus Agios, MiMedx, Iveric, Ardelyx, Novo Seeds, Axcella, NervGen

...and Cell Therapy and a professor of microbiology, physiological systems and biomedical research at the University of Massachusetts Medical School...
BioCentury | Aug 16, 2019
Emerging Company Profile

A-Alpha Bio retools yeast mating for high throughput drug discovery

...Younger said. The program is a collaboration with Lumen Biosciences Inc. and MassBiologics of the University of Massachusetts Medical School...
...status: Preclinical Founded: 2017 by David Younger and Randolph Lopez University collaborators: University of Washington, University of Massachusetts Medical School...
...Melinda Gates Foundation, Seattle, Wash. Kymera Therapeutics Inc., Cambridge, Mass. Lumen Biosciences Inc., Seattle, Wash. University of Massachusetts Medical School...
Items per page:
1 - 10 of 203
BioCentury | Jan 12, 2021
Emerging Company Profile

Atalanta’s next-gen RNAi branches deeper into brain, hooks Biogen and Genentech

...The sizes of the three components are undisclosed.The University of Massachusetts Medical School...
BioCentury | Aug 5, 2020
Emerging Company Profile

Nura reveals neuroprotective lead target, first part of its neurology one-two punch

...serves as chairman. The company’s scientific founders are Marc Freeman, a professor of neurobiology at University of Massachusetts Medical School...
BioCentury | Jun 26, 2020
Distillery Therapeutics

Promoting Golgi fragmentation to treat pancreatic cancer

...Natl. Acad. Sci. USA ; published online May 19, 2020 doi:10.1073/pnas.2005156117 CONTACT: Michael R. Green, University of Massachusetts Medical School...
...Mass. email: Michael.Green@umassmed.edu CONTACT: Narendra Wajapeyee, University of Alabama at Birmingham, Birmingham, Ala. email: nwajapey@uab.edu Claire Quang University of Massachusetts Medical School University...
BioCentury | Jun 11, 2020
Deals

June 10 Quick Takes: Lilly enters deal with Evox on exosome therapies; plus Sanofi-Alphamab, CSL-Vitaeris, Canbridge-UMass and Find’s debut

...therapies Canbridge Pharmaceuticals Inc. has initiated a research collaboration with the Gene Therapy Center at University of Massachusetts Medical School...
...University of Illinois in Chicago. Targets IL-6 - Interleukin-6 BioCentury Staff Eli Lilly and Co. Evox Therapeutics Ltd. Vitaeris Inc. Sanofi University of Massachusetts Medical School Alphamab...
BioCentury | May 9, 2020
Deals

Columbia’s peptide nucleic acid technology draws Fortress into rare discovery deal

...formation of gene therapy subsidiary Aevitas Therapeutics Inc., which has a research agreement with the University of Massachusetts Medical School...
BioCentury | Apr 17, 2020
Emerging Company Profile

Rgenta: enhancing interactions between RNA and RNA-binding proteins

...and CEO Simon Xi. Weng, who heads Rgenta’s scientific advisory board, is a professor at University of Massachusetts Medical School...
...Clinical status: Preclinical Founded: 2019 by Zhiping Weng, Simon Xi and Travis Wager University collaborators: University of Massachusetts Medical School...
BioCentury | Apr 10, 2020
Product Development

COVID-19 roundup: New immune targets to address pandemic; plus updates from CanSino, Arcturus, Fujifilm and more

...50 patients, will be conducted with Brigham and Women’s Hospital, Massachusetts General Hospital and the University of Massachusetts Medical School...
BioCentury | Jan 31, 2020
Distillery Therapeutics

Crry gene therapy to treat multiple sclerosis

...published online Dec. 26, 2019 doi:10.1016/j.immuni.2019.12.004 CONTACT: Dorothy P. Schafer, University of Massachusetts Medical School, Worcester, Mass. email: dorothy.schafer@umassmed.edu Claire Quang University of Massachusetts Medical School...
BioCentury | Nov 27, 2019
Company News

Management tracks: Ultragenyx COO to step down next year; plus Agios, MiMedx, Iveric, Ardelyx, Novo Seeds, Axcella, NervGen

...and Cell Therapy and a professor of microbiology, physiological systems and biomedical research at the University of Massachusetts Medical School...
BioCentury | Aug 16, 2019
Emerging Company Profile

A-Alpha Bio retools yeast mating for high throughput drug discovery

...Younger said. The program is a collaboration with Lumen Biosciences Inc. and MassBiologics of the University of Massachusetts Medical School...
...status: Preclinical Founded: 2017 by David Younger and Randolph Lopez University collaborators: University of Washington, University of Massachusetts Medical School...
...Melinda Gates Foundation, Seattle, Wash. Kymera Therapeutics Inc., Cambridge, Mass. Lumen Biosciences Inc., Seattle, Wash. University of Massachusetts Medical School...
Items per page:
1 - 10 of 203